Citigroup’s Intelligent Bio Solutions INBS Stock Holding History

Citigroup’s Portfolio INBS Stock Details INBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-76	Closed	-$724	–	6148
2025 Q4	$724	Sell	76 -859	-92%	-$6.99K	﹤0.01%	5562
2025 Q3	$9.54K	Buy	+935	New	+$15.1K	﹤0.01%	5039
2024 Q2	–	Sell	-796	Closed	-$33.6K	–	5678
2024 Q1	$33.6K	Buy	+796	New	+$33K	﹤0.01%	4835

Other funds holding INBS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Curio Wealth Annapolis, Maryland $293M AUM 14.23% 1-Year Est. Return

Citigroup's INBS Position: Q1 2026 in Review

Citigroup sold out of Intelligent Bio Solutions (INBS) in Q1 2026, closing a stake of 76 shares — an estimated $724 sold.

Citigroup first reported a position in INBS in Q1 2024 and held it in 3 quarters. The position peaked at $33.6K in Q1 2024. 9 funds tracked by Wall St. Rank hold INBS as of Q1 2026.

Citigroup reported no remaining Intelligent Bio Solutions position as of Q1 2026 after selling out during the quarter.
Citigroup sold 76 Intelligent Bio Solutions shares in Q1 2026, an estimated $724.
Citigroup first reported a position in Intelligent Bio Solutions in Q1 2024 and held it in 3 quarters.
Citigroup's Intelligent Bio Solutions position peaked at $33.6K in Q1 2024.
9 funds tracked by Wall St. Rank held Intelligent Bio Solutions as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.